➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Mallinckrodt
Merck
Boehringer Ingelheim
Moodys

Last Updated: January 24, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for BIIB074

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug BIIB074?

BIIB074 is an investigational drug.

There have been 12 clinical trials for BIIB074. The most recent clinical trial was a Phase 1 trial, which was initiated on April 30th 2018.

The most common disease conditions in clinical trials are Neuralgia, Trigeminal Neuralgia, and Radiculopathy. The leading clinical trial sponsors are Biogen, Convergence Pharmaceuticals, and [disabled in preview].

There are fifteen US patents protecting this investigational drug and one hundred and ninety-six international patents.

Recent Clinical Trials for BIIB074
TitleSponsorPhase
Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic PolyneuropathyBiogenPhase 1
802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal NeuralgiaBiogenPhase 3
Efficacy and Safety Study of BIIB074 in Participants With Trigeminal NeuralgiaBiogenPhase 3

See all BIIB074 clinical trials

Clinical Trial Summary for BIIB074

Top disease conditions for BIIB074
Top clinical trial sponsors for BIIB074

See all BIIB074 clinical trials

US Patents for BIIB074

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BIIB074   Start Trial Erythromelalgia treatment Convergence Pharmaceuticals Limited (Maidenhead, GB)   Start Trial
BIIB074   Start Trial Process for preparing alpha-carboxamide pyrrolidine derivatives Convergence Pharmaceuticals Limited (GB)   Start Trial
BIIB074   Start Trial Compounds Glaxo Group Limited (Greenford, Middlesex, GB)   Start Trial
BIIB074   Start Trial Compounds Convergence Pharmaceuticals Limited (London, GB)   Start Trial
BIIB074   Start Trial Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-- 3S-yl-) Glaxo Group Limited (Greenford, Middlesex, GB)   Start Trial
BIIB074   Start Trial Methods of treating bipolar disorders Convergence Pharmaceuticals Limited (London, GB)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BIIB074

Drugname Country Document Number Estimated Expiration Related US Patent
BIIB074 Denmark DK3200783 2034-10-03   Start Trial
BIIB074 European Patent Office EP3200783 2034-10-03   Start Trial
BIIB074 Spain ES2751688 2034-10-03   Start Trial
BIIB074 United Kingdom GB201417497 2034-10-03   Start Trial
BIIB074 Croatia HRP20191434 2034-10-03   Start Trial
BIIB074 Hungary HUE047940 2034-10-03   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Mallinckrodt
Merck
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.